References
- Druker B J, Guilhot F, O'Brien S G, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417
- Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol 2003; 40: 79–86
- Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880
- Sokal J E, Gomez G A, Baccarani M, Tura S, Clarkson B D, Cervantes F, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988; 72: 294–298
- Ohyashiki J H, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002; 21: 680–687
- Kim N W, Piatyszek M A, Prowse K R, Harley C B, West M D, Ho P L, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011–2015
- Ohyashiki K, Ohyashiki J H, Iwama H, Hayashi S, Shay J W, Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 1997; 11: 190–194
- Yamada O, Kawauchi K, Akiyama M, Ozaki K, Motoji T, Adachi T, et al. Resistance to imatinib in leukemic cells with increased telomerase activity. Leuk Lymphoma, in press
- Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki J H, Abe K, et al. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin Cancer Res 2002; 8: 3341–3347
- Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005; 92: 1881–1891
- Campbell L J, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006; 20: 671–679
- Drummond M W, Hoare S F, Monaghan A, Graham S M, Alcorn M J, Keith W N, et al. Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia 2005; 19: 381–389
- Shay J W, Keith W N. Targeting telomerase for cancer therapeutics. Br J Cancer 2008; 98: 677–683